Category: Drug Safety Alerts
-
NAION News Reports: GLP-1 Side Effect Harms Vision, Eyes
Ozempic, Wegovy, Mounjaro, Zepbound Associated With Loss of Eyesight (Posted by Tom Lamb at Drug Injury Watch) Non-arteritic anterior ischemic optic neuropathy (NAION) is a GLP-1 side effect that harms vision by causing damage to the eyes.…
-
Tavneos Liver Risks Confirmed by Medical Registry Data in the US
Possible Legal Compensation Cases for People Who Developed Tavneos Liver Injury (Posted by Tom Lamb at Drug Injury Watch) The FDA approved Tavneos (avacopan) in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). We had been…
-
Ozempic Eye Problems Side Effect Warnings Not In US Drug Label
Ozempic NAION Risk Is Highlighted In Other Countries, So Why Not Here? (Posted by Tom Lamb at Drug Injury Watch) The current Prescribing Information document for Ozempic (Revised: 5/2026 version) in the US does not include any…
-
Semaglutide-associated Vision Loss Due to NAION – New Medical Report, May 2026
Ozempic, Wegovy, and Rybelsus Are Semaglutide Drugs Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (Posted by Tom Lamb at Drug Injury Watch) Before we direct you to a new medical report about semaglutide-associated vision loss due…
-
Ozempic And Other GLP-1RA Use Associated With NAION Eye Side Effect
New 2026 Medical Article Published By JAMA Network Open Investigates Drug Safety Issue (Posted by Tom Lamb at Drug Injury Watch) An increasingly known but still-developing drug safety issue is that of Ozempic and other GLP-1RA use…
-
Tavneos Warnings For VBDS Liver Side Effect Increased In April 2026
Tavneos Drug Label Change By Amgen Just 2 Days After Tavneos Drug Recall Statement By FDA (Posted by Tom Lamb at Drug Injury Watch) The Tavneos drug safety issue has an interesting new development. On April 29,…
-
Tavneos Liver Injury Drug Safety Communication Issued by FDA in Late March 2026
Just 2 Months Earlier, Amgen Refused an FDA Request to Withdraw Tavneos; Will There Be a Tavneos Recall Soon? (Posted by Tom Lamb at Drug Injury Watch) On March 31, 2026, the FDA issued a Tavneos liver…
-
Wegovy and Ozempic Vision Loss: Wegovy Rate 5x Higher vs. Ozempic, Men 3x More Often vs. Women
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Semaglutide Study 2026 Data Analysis (Posted by Tom Lamb at Drug Injury Watch) A March 2026 British Journal of Ophthalmology medical journal article, “Ischemic optic neuropathy with semaglutide: global observational analysis…
-
While Rybelsus Pills Are Being Replaced With Pills Called Ozempic, Semaglutide NAION Risk Remains
But the January 2026 Rybelsus-Ozempic Drug Label Still Has No Warnings for NAION Vision Loss Side Effect (Posted by Tom Lamb at Drug Injury Watch) The “Revised: 1/2026” Prescribing Information document for “RYBELSUS and OZEMPIC tablets” caused…
-
Risk of NAION With Semaglutide Medicines is 2 Times Higher Than SGLT2i Diabetes Drugs
2026 Medical Article Links NAION to Ozempic, Wegovy, and Rybelsus, Again, With New Study (Posted by Tom Lamb at Drug Injury Watch) This drug safety issue of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide-containing drugs…